Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Disease × vistusertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 3 Stomach Neoplasms 2 Solid Tumor 2 Recurrence 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Small Cell Lung Carcinoma 1 Prostatic Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Muscle Invasive Bladder Cancer 1 Meningioma 1 Lung Neoplasms 1 Glioblastoma 1 Estrogen Receptor Positive Breast Cancer 1 Endometrial Neoplasms 1 Disease 1 DLBCL 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Carcinoma 1 Advanced Solid Malignancies 1 Advanced Metastatic Breast Cancer 1 Advanced Cancer 1 Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 6 Mammography 4 Dexamethasone 4 Cyclophosphamide 4 Colonoscopy 4 Blood Specimen Collection 4 Tomography, X-Ray Computed 3 Prednisone 3 Positron Emission Tomography Computed Tomography 3 Melphalan 3 Lenalidomide 3 weifuchun 2 pembrolizumab 2 fluciclovine F-18 2 daratumumab 2 Surveys and Questionnaires 2 Preoperative Exercise 2 Positron-Emission Tomography 2 Methods 2 Magnetic Resonance Imaging 2 Injections 2 Gemcitabine 2 Cytarabine 2 Control Groups 2 Biopsy, Fine-Needle 2 Biopsy 2 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2 vistusertib 1 venetoclax 1 tivozanib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02064608 2019-07-17

CaNCaP02

Cambridge University Hospitals NHS Foundation Trust

Phase 1 Completed

Disease, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡